TITLE:
Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder

CONDITION:
Schizophrenic Disorders

INTERVENTION:
Intramuscular olanzapine depot

SUMMARY:

      This is a long-term, open-label clinical study designed to enable longer-term treatment of
      patients completing other clinical studies with intramuscular olanzapine depot.

      Key objectives of the study are to:

        -  Determine how well intramuscular (IM) olanzapine depot works during long-term
           treatment,

        -  Evaluate the safety and tolerability of IM olanzapine depot during long-term treatment,

        -  Determine the blood levels of IM olanzapine depot in patients during long-term
           treatment
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 76 Years
Criteria:

        Inclusion Criteria:

          -  Patients must have schizophrenia

          -  Female patients of childbearing potential must be using a medically accepted means of
             contraception

          -  Patients must have completed (within 10 days) another IM olanzapine depot study if
             permitted by that study's protocol.

        Exclusion Criteria:

          -  Patients must not have participated in a clinical trial of another investigational
             drug, including olanzapine, within 1 month (30 days) prior to study entry

          -  Female patients must not be pregnant or breast-feeding

          -  Patients must not be experiencing acute, serious or unstable medical conditions other
             than schizophrenia or schizoaffective disorder

          -  Patients must not have a substance (except nicotine or caffeine) dependence within
             the past 30 days
      
